# Avoro Capital Advisors LLC 13F Q2 2026: $11.1 billion

Avoro Capital Advisors LLC reported $11.1 billion in 13F securities across 26 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was United Therapeutics Corp Del at $1.5 billion, 13.5% of the reported value. Since Q1 2026 it opened 3 new positions and exited 9.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $11,136,250,185
- Positions: 26
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1633313
- Form 13F file number: 028-16573
- CRD number: 154091
- Business address: 110 Greene Street Suite 800, New York, NY 10012
- SEC filing: [0001104659-26-096427](https://www.sec.gov/Archives/edgar/data/1633313/000110465926096427/0001104659-26-096427-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/avoro-capital-advisors-llc-154091)

## Top 25 holdings by value

The largest of 26 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [United Therapeutics Corp Del](https://specstream.ai/data/institutional-holders/united-therapeutics-corp-del-91307c102) | COM | 2,777,777 | $1.51 billion | +147,777 |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 5,111,111 | $1.36 billion | New |
| [Krystal Biotech Inc](https://specstream.ai/data/institutional-holders/krystal-biotech-inc-501147102) | COM | 2,888,888 | $1.07 billion | No change |
| [Madrigal Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/madrigal-pharmaceuticals-inc-558868105) | COM | 1,833,333 | $984.4 million | +15,152 |
| [Argenx Se](https://specstream.ai/data/institutional-holders/argenx-se-04016x101) | SPONSORED ADR | 1,000,000 | $927.8 million | No change |
| [Arrowhead Pharmaceuticals in](https://specstream.ai/data/institutional-holders/arrowhead-pharmaceuticals-in-04280a100) | COM | 11,355,555 | $925.6 million | +655,556 |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 7,474,747 | $857.1 million | No change |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 2,297,000 | $430.2 million | -47,444 |
| [Cytokinetics Inc](https://specstream.ai/data/institutional-holders/cytokinetics-inc-23282w605) | COM NEW | 4,999,999 | $425.9 million | +1,666,666 |
| [Celcuity Inc](https://specstream.ai/data/institutional-holders/celcuity-inc-15102k100) | COM | 3,400,000 | $355.7 million | +25,000 |
| [Structure Therapeutics Inc](https://specstream.ai/data/institutional-holders/structure-therapeutics-inc-86366e106) | SPONSORED ADS | 6,555,555 | $351.8 million | No change |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 5,777,777 | $348.7 million | No change |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 7,188,888 | $338.2 million | +2,188,888 |
| [Uniqure NV](https://specstream.ai/data/institutional-holders/uniqure-nv-n90064101) | SHS | 6,727,777 | $309.9 million | +768,182 |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 5,723,888 | $245.6 million | -165,000 |
| [Taysha Gene Therapies Inc](https://specstream.ai/data/institutional-holders/taysha-gene-therapies-inc-877619106) | COM SHS | 23,888,888 | $162.7 million | +2,188,888 |
| [Ocular Therapeutix Inc](https://specstream.ai/data/institutional-holders/ocular-therapeutix-inc-67576a100) | COM | 12,540,000 | $123.1 million | +225,000 |
| [Damora Therapeutics Inc](https://specstream.ai/data/institutional-holders/damora-therapeutics-inc-36322q206) | COM NEW | 3,783,000 | $98.4 million | No change |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 1,925,150 | $70.7 million | New |
| [GH Research PLC](https://specstream.ai/data/institutional-holders/gh-research-plc-g3855l106) | ORDINARY SHARES | 1,800,000 | $48.4 million | No change |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 2,500,000 | $45.9 million | +1,000,000 |
| [Septerna Inc](https://specstream.ai/data/institutional-holders/septerna-inc-81734d104) | COM | 1,337,500 | $44.8 million | No change |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 2,333,333 | $43.1 million | +923,333 |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 1,444,039 | $36.1 million | New |
| [Whitehawk Therapeutics Inc](https://specstream.ai/data/institutional-holders/whitehawk-therapeutics-inc-00032q104) | COM | 2,849,402 | $13.1 million | No change |

## New positions in Q2 2026

3 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Ascendis Pharma A/S](https://specstream.ai/data/institutional-holders/ascendis-pharma-a-s-k08588103) | ORD SHS | 5,111,111 | $1.36 billion |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 1,925,150 | $70.7 million |
| [Faeth Therapeutics Inc](https://specstream.ai/data/institutional-holders/faeth-therapeutics-inc-81728a207) | COM NEW | 1,444,039 | $36.1 million |

## Positions exited in Q2 2026

9 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Ascendis Pharma A/S | SPONSORED ADR | 5,062,500 | $1.16 billion |
| Apellis Pharmaceuticals Inc | COM | 12,222,222 | $491.7 million |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 11,430,455 | $454 million |
| Terns Pharmaceuticals Inc | COM | 5,695,000 | $300.2 million |
| Soleno Therapeutics Inc | COM | 2,300,000 | $77 million |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 1,200,000 | $42.4 million |
| United Therapeutics Corp Del | COM (call) | 380,000 | $10.3 million |
| [Mannkind Corp](https://specstream.ai/data/institutional-holders/mannkind-corp-56400p706) | COM NEW | 2,200,000 | $5.4 million |
| Celcuity Inc | COM (call) | 200,000 | $3.1 million |

## Also on SpecStream

- [Avoro Capital Advisors LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1633313/000110465926096427/0001104659-26-096427-index.htm)
- [Avoro Capital Advisors LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/avoro-capital-advisors-llc-154091)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Psychology practices in New York, New York](https://specstream.ai/data/businesses/psychology-practices/new-york-new-york-united-states)
- [Dermatology practices in New York, New York](https://specstream.ai/data/businesses/dermatology-practices/new-york-new-york-united-states)
- [Public schools in New York, New York](https://specstream.ai/data/businesses/public-schools/new-york-new-york-united-states)
- [Dim sum restaurants in New York, New York](https://specstream.ai/data/businesses/dim-sum-restaurants/new-york-new-york-united-states)
- [Radiology practices in New York, New York](https://specstream.ai/data/businesses/radiology-practices/new-york-new-york-united-states)
- [Divorce and family law firms in New York, New York](https://specstream.ai/data/businesses/divorce-and-family-law-firms/new-york-new-york-united-states)
